Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment

被引：0

作者：

Wang, Michael L. ^{[1
]}

Shah, Nirav N. ^{[2
]}

Jurczak, Wojciech ^{[3
,6
]}

Zinzani, Pier Luigi ^{[4
,5
]}

Eyre, Toby A.

Cheah, Chan Y. ^{[7
,8
,9
]}

Ujjani, Chaitra S. ^{[10
]}

Izutsu, Koji ^{[11
]}

Ma, Shuo ^{[12
]}

Flinn, Ian ^{[13
]}

Alencar, Alvaro J. ^{[14
]}

Lewis, David ^{[15
]}

Patel, Krish ^{[16
]}

Maddocks, Kami ^{[17
]}

Wang, Yucai ^{[18
]}

Munir, Talha ^{[19
]}

Zelenetz, Andrew D. ^{[20
]}

Balbas, Minna ^{[21
]}

Tsai, Donald E. ^{[21
]}

Wang, Chunxiao ^{[22
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[3] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[4] IRCCS Azienda Osped Univ Bologna Ist Ematol, Seragnoli, Italy

[5] Univ Bologna, Dipartimento Med Specialist Diag & Sperimentale, Bologna, Italy

[6] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[7] Linear Clin Res, Perth, WA, Australia

[8] Sir Charles Gairdner Hosp, Perth, WA, Australia

[9] Univ Western Australia, Med Sch, Perth, WA, Australia

[10] Univ Washington, Fred Hutchinson Canc Res Ctr, Washington, DC USA

[11] Natl Canc Ctr, Dept Hematol, Tokyo, Japan

[12] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA

[13] Sarah Cannon Res Inst & Tennessee Oncol, Nashville, TN USA

[14] Sylvester Comprehens Canc Ctr, Miami, FL USA

[15] Plymouth Hosp NHS Trust Derriford Hosp, Plymouth, Devon, England

[16] Swedish Canc Inst, Ctr Blood Disorders & Cellular Therapy, Seattle, WA USA

[17] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[18] Mayo Clin, Div Hematol, Rochester, MN USA

[19] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[20] Memorial Sloan Kettering Canc Ctr, New York, NY USA

[21] Loxo Lilly, Indianapolis, IN USA

[22] Eli Lilly & Co, Indianapolis, IN USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

MCL; BTK-inhibitor; pirtobrutinib; TP53; mutation;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MCL-155

引用

页码：S459 / S459

页数：1

共 50 条

[1] Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
Shah, Nirav Niranjan
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan
Ujjani, Chaitra Shankar
Izutsu, Koji
Ma, Shuo
Flinn, Ian W.
Alencar, Alvaro Jose
Lewis, David John
Patel, Krish
Maddocks, Kami J.
Wang, Yucai
Munir, Talha
Zelenetz, Andrew David
Balbas, Minna
Tsai, Donald E.
Wang, Chunxiao
Wang, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUIN
Lewis, David John
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutzu, Koji
Gerson, James N.
Flinn, Ian
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna
Patel, Krish
Woyach, Jennifer
Lamanna, Nicole
Wang, Yucai
Tam, Constantine
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew
Jain, Preteesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 108 - 109
[3] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutsu, Koji
Gerson, James N.
Flinn, Ian W.
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna M.
Patel, Krish
Woyach, Jennifer A.
Lamanna, Nicole
Wang, Yucai
Tam, Constantine S.
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew D.
Jain, Preetesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo B.
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BLOOD, 2022, 140 : 9368 - 9372
[4] Pirtobrutinib, A Highly Selective, Non-covalent (Reversible) BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav
Alencar, Alvaro
Gerson, James
Patel, Manish
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John
Lamanna, Nicole
Cohen, Johnathon
Barve, Minal
Ghia, Paolo
Eyre, Toby
Zinzani, Pier Luigi
Ujjani, Chaitra
Koh, Youngil
Izutsu, Koji
Lech-Maranda, Ewa
Tam, Constantine
Sundaram, Suchitra
Yin, Ming
Nair, Binoj
Tsai, Donald
Balbas, Minna
Mato, Anthony
Cheah, Chan
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 101 - 104
[5] Pirtobrutinib, a Highly Selective, NonCovalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
Cohen, Jonathon B.
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David J.
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Zinzani, Pier Luigi
Ujjani, Chaitra S.
Koh, Youngil
Izutsu, Koji
Lech-Maranda, Ewa
Tam, Constantine S.
Sundaram, Suchitra
Yin, Ming
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S394 - S395
[6] Pirtobrutinib, A Next Generation, Highly Selective, Non-covalent BTK Inhibitor In Previously Treated Mantle Cell Lymphoma: Updated Results From The Phase 1/2 BRUIN Study
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan
Lewis, Katharine
Fenske, Timothy
Coombs, Catherine C.
Flinn, Ian
Lewis, David
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer
Pagel, John M.
Lamanna, Nicole
Cohen, Johnathon B.
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Mato, Anthony R.
Cheah, Chan Y.
Wang, Michael L.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 170 - 171
[7] Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, Davi John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal A.
Ghia, Paolo
Eyre, Toby A.
Zinzani, Pier Luigi Luigi
Ujjani, Chaitra S.
Koh, Youngil
Izutsu, Koji
Lech-Maranda, Ewa
Tam, Constantine S.
Sundaram, Suchitra
Yin, Ming
Nair, Binoj
Balbas, Minna
Tsai, Donald
Mato, Anthony R.
Cheah, Chan Yoon
BLOOD, 2021, 138
[8] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Mato, Anthony R.
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Shah, Nirav N.
Coombs, Catherine C.
Ujjani, Chaitra S.
Patel, Manish R.
Fakhri, Bita
Cheah, Chan Y.
Alencar, Alvaro J.
Cohen, Jonathon B.
Gerson, James N.
Flinn, Ian W.
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Hernandez-Ilizaliturri, Francisco
Zinzani, Pier Luigi
Balbas, Minna
Nair, Binoj
Abada, Paolo B.
Wang, Chunxiao
Wang, Denise
Tsai, Donald E.
Wierda, William G.
Jurczak, Wojciech
BLOOD, 2022, 140 : 2316 - 2320
[9] Pirtobrutinib, a Next-Generation, Highly Selective, Noncovalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
[10] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN
Munir, Talha
Mato, Anthony R.
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Patel, Krish
Eyre, Toby A.
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Shah, Nirav N.
Coombs, Catherine C.
Ujjani, Chaitra S.
Patel, Manish R.
Fakhri, Bita
Cheah, Chan Y.
Alencar, Alvaro J.
Cohen, Jonathon B.
Gerson, James N.
Flinn, Ian W.
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Hernandez-Ilizaliturri, Francisco
Zinzani, Pier Luigi
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Denise
Tsai, Donald E.
Wierda, William G.
Jurczak, Wojciech
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 110 - 111

← 1 2 3 4 5 →